Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor... see more

Recent & Breaking News (OTCQB:NWBO)

NW BIO Announces Registered Direct Offering Of $1.75 Million

PR Newswire September 20, 2017

DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference

PR Newswire September 1, 2017

NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds

PR Newswire June 22, 2017

Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today

PR Newswire June 5, 2017

NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors

PR Newswire March 23, 2017

NW BIO Announces Registered Direct Offering Of $7.5 Million

PR Newswire March 17, 2017

NW Bio Reaches Agreement With Convertible Note Holders

PR Newswire March 10, 2017

NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached

PR Newswire February 6, 2017

NW Bio Presenting At Phacilitate Immunotherapy World Conference

PR Newswire January 18, 2017

NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $10.0 MILLION WITH INSTITUTIONAL INVESTORS

PR Newswire December 20, 2016

NW Bio Announces Initiation Of Trading On The OTCQB Marketplace Starting On Monday Morning, December 19, 2016

PR Newswire December 19, 2016

NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer

PR Newswire December 8, 2016

NW Bio Announces Decision to Voluntarily Withdraw from Nasdaq Listing and Begin Trading on OTC Market

PR Newswire December 7, 2016

Biotech Stocks on Investors' Radar -- Northwest Biotherapeutics, ACADIA Pharma, Acorda Therapeutics, and Ultragenyx Pharma

PR Newswire December 5, 2016

NW Bio Announces Phase II Clinical Trial Program Combining DCVax®-L and Pembrolizumab (Keytruda®) for Colorectal Cancer

PR Newswire November 17, 2016

NW BIO Announces Registered Direct Offering

PR Newswire October 21, 2016

NW Bio Presents Further DCVax®-Direct Phase I Trial Information On Individual Patient Survival At NY Cancer Immunotherapy Conference

PR Newswire September 29, 2016

NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference in London

PR Newswire September 21, 2016

NW Bio Enters First 180-Day Grace Period Relating To Non-Compliance With Nasdaq $1.00 Per Share Bid Requirement

PR Newswire June 30, 2016

Pre-Market Review on Biotechnology Equities -- Northwest Biotherapeutics, Titan Pharma, Ultragenyx Pharma, and Athersys

PR Newswire June 29, 2016